Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine Priming Before HSCT for High-Risk Myeloid Malignancies
NCT02497404Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Started Feb 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02497404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497404.